Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

CGM Substudy, Addendum 2, of the Following Exenatide LAR Protocol 2993LAR-105: A Randomized, Open-Label, Multicenter, Comparator Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00803920

Enrollment

Registered

2008-12-08

Start date

2006-12-31

Completion date

2008-02-29

Last updated

2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

exenatide twice daily or once weekly, continuous glucose monitoring

Brief summary

The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* participant in Amylin Protocol 2993LAR-105 * at least 16 years of age * type 2 diabetes being treated with stable regiment of metformin, SU, TZD, combination of metformin/SU, combination metformin/TZD, combination SU/TZD * A1c 7.1 - 11 * fasting glucose less than 280 at screening * BMI 25 - 45 * stable body weight 6 months prior to screening * not pregnant and willing to practice birth control * physical exam & ECG not clinically significant * lab values judged not to be clinically significant * able to understand & sign consent form

Exclusion criteria

* clinically significant medical condition as judged by investigator * drug or alcohol abuse * previous use of exenatide or any GLP-1 analog * has used any investigational drug in the past 30 days prior to screening * is currently using: alpha-glucosidase inhibitor, insulin, drugs that affect GI motility, use of systemic corticosteroids, use of medications with addictive potential, prescription or OTC weight-loss medications * has donated blood within 60 days of screening, or is planning to donate during the study * has had major surgery or blood transfusion within 2 months of screening * has had a surgical procedure that may impact gastric emptying * has any allergies or hypersensitivity to any component of study treatment * is an immediate family member of personnel affiliated with the study at the investigative site * is employed by Amylin, Lilly or Alkermes

Design outcomes

Primary

Measure	Time frame	Description
Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site.	2 week periods of time - 3 times during study:	Baseline CGM will be performed from Visit 2 to Visit 3 for approximately 14 days followed by a second CGM period from Visit 3 to Visit 6 for approximately 17 days. At Week 28, two weeks after Visit 14 (Week 26), subjects will be instructed to begin CGM and to continue through Visit 20 (Week 30) for Group A subjects or Visit 22 (Week 32) for Group B subjects. At Week 50, two weeks after Visit 28 (Week 48), subjects will be instructed to begin the final CGM period and to continue monitoring until the next study visit at Visit 29 (Week 52)

Countries

United States

Outcome results